C.R. Bard (BCR) Receives Analyst Rating

C.R. Bard (BCR) : 1 brokerage houses believe that C.R. Bard (BCR) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 12 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on C.R. Bard (BCR). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 14 Wall Street Analysts endorse the stock as a Hold with a rating of 2.79.

C.R. Bard (BCR) : The highest level C.R. Bard (BCR) is projected to reach is $264 for the short term and the lowest estimate is at $232. The consolidated price target from 9 rating analysts who initiate coverage on the stock is $242.33 and the possibility the share price can swing is $10.45.


Also, Equity Analysts at the Barclays maintains the rating on C.R. Bard (NYSE:BCR). The brokerage firm has issued a Equalweight rating on the shares. The Analysts at the ratings agency raises the price target from $224 per share to $235 per share. The rating by the firm was issued on July 27, 2016.

C.R. Bard (NYSE:BCR): After opening at $221.02, the stock dipped to an intraday low of $217.1 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $225.67 and the buying power remained strong till the end. The stock closed at $223.63 for the day, a gain of 3.10% for the day session. The total traded volume was 810,271. The stocks close on the previous trading day was $216.91.

C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Companys vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.